https://www.selleckchem.com/products/azd9291.html
01). Treatment with ribavirin was not associated with a difference in the time to clinical improvement (P=0.48, HR=0.88, 95% CI=0.63-1.25). There were also no significant differences between-group in SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and the length of hospital stay. In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment. In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment. The rapi
Like
Comment
Share
